| __timestamp | Iovance Biotherapeutics, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 16606000 |
| Thursday, January 1, 2015 | 999000 | 21497000 |
| Friday, January 1, 2016 | 978000 | 25462000 |
| Sunday, January 1, 2017 | 952000 | 28195000 |
| Monday, January 1, 2018 | 956000 | 33078000 |
| Tuesday, January 1, 2019 | 8122999 | 36523000 |
| Wednesday, January 1, 2020 | 8712000 | 41455000 |
| Friday, January 1, 2021 | 13980000 | 74400000 |
| Saturday, January 1, 2022 | 21135000 | 101582000 |
| Sunday, January 1, 2023 | 10755000 | 112903000 |
Unlocking the unknown
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Veracyte, Inc. and Iovance Biotherapeutics, Inc. from 2014 to 2023. Over this period, Veracyte's cost of revenue surged by approximately 580%, reflecting its aggressive growth and expansion strategies. In contrast, Iovance Biotherapeutics experienced a more modest increase of around 15%, indicating a different operational focus.
These trends highlight the contrasting financial strategies and market positions of these two biotech firms.
Analyzing Cost of Revenue: Eli Lilly and Company and Veracyte, Inc.
Cost of Revenue Trends: AbbVie Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue: Key Insights for AstraZeneca PLC and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Veracyte, Inc.
Analyzing Cost of Revenue: Bristol-Myers Squibb Company and Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Viatris Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Veracyte, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: PTC Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Veracyte, Inc. vs Amphastar Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Wave Life Sciences Ltd.